Compare DOMO & RCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DOMO | RCEL |
|---|---|---|
| Founded | 2010 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 477.0M | 114.3M |
| IPO Year | 2018 | N/A |
| Metric | DOMO | RCEL |
|---|---|---|
| Price | $8.66 | $3.34 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 8 | 5 |
| Target Price | ★ $14.38 | $11.75 |
| AVG Volume (30 Days) | ★ 918.6K | 196.2K |
| Earning Date | 12-04-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $318,002,000.00 | $72,401,000.00 |
| Revenue This Year | $2.32 | $13.12 |
| Revenue Next Year | $2.72 | $27.56 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 20.59 |
| 52 Week Low | $6.01 | $3.33 |
| 52 Week High | $18.49 | $14.16 |
| Indicator | DOMO | RCEL |
|---|---|---|
| Relative Strength Index (RSI) | 27.29 | 33.79 |
| Support Level | $8.40 | $3.33 |
| Resistance Level | $9.27 | $3.58 |
| Average True Range (ATR) | 0.55 | 0.18 |
| MACD | -0.10 | 0.00 |
| Stochastic Oscillator | 6.75 | 13.24 |
Domo Inc provides a cloud-based platform that digitally connects all the data, systems, and people in an organization, giving them access to real-time data and insights and allowing them to manage their business from their smartphones. The company offers a platform to its customers as a subscription-based service. Users receive notifications on any device and immediately act on the invitation, after which the system can write back to the original system of record. The company derives revenue from subscriptions to its cloud-based platform and professional services.
Avita is a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult and paediatric patients in the US and an expanded indication for soft-tissue reconstruction. It is currently in rollout across the approximately 136 US burn centers. Despite having product approval in Australia, Europe, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region. However, it is expected to launch in Japan via distribution partner Cosmotec in second-half fiscal 2022. Avita is domiciled, and has its primary listing, in the US.